Twenty-four hours of activity of cetirizine and fexofenadine in the skin (Q43602361)

25 November 2017

Twenty-four hours of activity of cetirizine and fexofenadine in the skin (English)

1 reference

25 November 2017

Purohit A

1

1 reference

25 November 2017

Duvernelle C

2

1 reference

25 November 2017

Melac M

3

1 reference

25 November 2017

Pauli G

4

1 reference

25 November 2017

Frossard N

5

1 reference

25 November 2017

1 April 2001

1 reference

Annals of Allergy, Asthma & Immunology

25 November 2017

1 reference

25 November 2017

86

1 reference

25 November 2017

4

1 reference

25 November 2017

387-392

1 reference

Urticaria: clinical efficacy of cetirizine in comparison with hydroxyzine and placebo

25 November 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962483-0

7 January 2021

Cetirizine and astemizole therapy for chronic idiopathic urticaria: a double-blind, placebo-controlled, comparative trial

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962483-0

7 January 2021

Comparative study of cetirizine and terfenadine versus placebo in the symptomatic management of seasonal allergic rhinitis

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962483-0

7 January 2021

Comparative outdoor study of the efficacy, onset and duration of action, and safety of cetirizine, loratadine, and placebo for seasonal allergic rhinitis

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962483-0

7 January 2021

Inhibition of histamine-induced nasal obstruction by cetirizine in allergic rhinitis

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962483-0

7 January 2021

Onset of action in the nasal antihistaminic effect of cetirizine and loratadine in patients with allergic rhinitis

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962483-0

7 January 2021

Nasal effect of cetirizine and loratadine at 24 hours in patients with allergic rhinitis.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962483-0

7 January 2021

A double-blind, single-dose, crossover comparison of cetirizine, terfenadine, loratadine, astemizole, and chlorpheniramine versus placebo: suppressive effects on histamine-induced wheals and flares during 24 hours in normal subjects

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962483-0

7 January 2021

Consistency of the efficacy of cetirizine and ebastine on skin reactivity

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962483-0

7 January 2021

A double-blind, single-dose, crossover comparison of cetirizine, ebastine, epinastine, fexofenadine, terfenadine, and loratadine versus placebo: suppression of histamine-induced wheal and flare response for 24 h in healthy male subjects

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962483-0

7 January 2021

A comparison of Cetirizine, Ebastine, Epinastine, Fexofenadine, Terfenadine, and Loratadine versus placebo in suppressing the cutaneous response to histamine

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962483-0

7 January 2021

Consistency and efficacy of cetirizine (10 mg) versus ebastine (20 mg) at 4 h on skin reactivity

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962483-0

7 January 2021

H1-receptor antagonists: safety issues

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962483-0

7 January 2021

The systemic safety of fexofenadine HCl.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962483-0

7 January 2021

Peripheral H1-blockade effect of fexofenadine

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962483-0

7 January 2021

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962483-0

1 reference

7 January 2021

Efficacy and safety of fexofenadine hydrochloride for treatment of seasonal allergic rhinitis

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962483-0

7 January 2021

Effectiveness and safety of fexofenadine, a new nonsedating H1-receptor antagonist, in the treatment of fall allergies

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962483-0

7 January 2021

Double-blind, placebo-controlled study comparing the efficacy and safety of fexofenadine hydrochloride (120 and 180 mg once daily) and cetirizine in seasonal allergic rhinitis

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962483-0

7 January 2021

Once-daily fexofenadine HCl improves quality of life and reduces work and activity impairment in patients with seasonal allergic rhinitis

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962483-0

7 January 2021

Safety and efficacy of once-daily fexofenadine HCl in the treatment of autumn seasonal allergic rhinitis.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962483-0

7 January 2021

A double-blind, placebo-controlled trial of fexofenadine HCl in the treatment of chronic idiopathic urticaria.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962483-0

7 January 2021

Cetirizine. A review of its pharmacological properties and clinical potential in allergic rhinitis, pollen-induced asthma, and chronic urticaria

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962483-0

7 January 2021

In vitro inhibition of human liver drug metabolizing enzymes by second generation antihistamines

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962483-0

7 January 2021

The metabolism of antihistamines and drug interactions: the role of cytochrome P450 enzymes

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962483-0

7 January 2021

Gas chromatographic method for the determination of cetirizine in plasma

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962483-0

7 January 2021

Pharmacokinetics, pharmacodynamics, and tolerance of single- and multiple-dose fexofenadine hydrochloride in healthy male volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962483-0

7 January 2021

Precision of skin prick and puncture tests with nine methods

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962483-0

7 January 2021

Comparing the H1 profile of second-generation antihistamines

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962483-0

7 January 2021

10.1016/S1081-1206(10)62483-0

Identifiers

DOI

1 reference

25 November 2017

1 reference